ClinicalTrials.Veeva
Menu

Find clinical trials for Chronic Lymphocytic Leukemia in Pittsburgh, PA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Chronic Lymphocytic Leukemia
Leukemia
Lymphoid Leukemia
Lymphoma
B-Cell Lymphoma
Mantle-Cell Lymphoma
Diffuse Large B-Cell Lymphoma

Chronic Lymphocytic Leukemia trials near Pittsburgh, PA, USA:

A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors (CaDAnCe-302)

or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic...

Enrolling
Chronic Lymphocytic Leukemia
CLL
Drug: Bendamustine
Drug: Rituximab

Phase 3

BeiGene
BeiGene

Wheeling, West Virginia, United States and 121 other locations

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL...

Enrolling
Lymphoma, Small Lymphocytic
Leukemia, Lymphocytic, Chronic, B-Cell
Biological: JCAR017 (lisocabtagene maraleucel) + venetoclax
Biological: JCAR017 (lisocabtagene maraleucel) + ibrutinib

Phase 1, Phase 2

Juno Therapeutics

Pittsburgh, Pennsylvania, United States and 82 other locations

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic...

Enrolling
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Rituximab
Drug: Sonrotoclax

Phase 3

BeiGene
BeiGene

Pittsburgh, Pennsylvania, United States and 176 other locations

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults with Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

ALLO-501A in adults with relapsed or refractory large B-cell lymphoma and assess the safety of ALLO-501A in adults with relapsed or refractory chronic...

Active, not recruiting
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
Drug: Fludarabine
Biological: ALLO-647

Phase 1, Phase 2

Allogene Therapeutics

Pittsburgh, Pennsylvania, United States and 22 other locations

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL (AMPLIFY)

The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination wit...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Venetoclax
Drug: Obinutuzumab

Phase 3

Acerta Pharma
Acerta Pharma

Pittsburgh, Pennsylvania, United States and 169 other locations

Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia

this approach to reliably generate product and to safely administer the product to patients who have B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia...

Enrolling
B Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Drug: Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous)

Phase 2

John Lister

Pittsburgh, Pennsylvania, United States

First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma (EPCORE™ NHL-1)

The purpose of this trial is to measure the following in participants with relapsed and/or refractory B-cell lymphoma who receive epcoritamab, an ant...

Active, not recruiting
Small Lymphocytic Lymphoma (SLL)
Aggressive B-cell Non-Hodgkin Lymphoma (aNHL)
Biological: Epcoritamab

Phase 1, Phase 2

Genmab
Genmab

Pittsburgh, Pennsylvania, United States and 84 other locations

9-ING-41 in Patients with Advanced Cancers

GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and e...

Active, not recruiting
Acute T Cell Leukemia Lymphoma
Neoplasm of Lung
Drug: Gemcitabine - 21 day cycle
Drug: 9-ING-41

Phase 2

Actuate Therapeutics

Pittsburgh, Pennsylvania, United States and 65 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems